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Abstract
Purpose Adequate dosimetry is mandatory for effective
and safe peptide receptor radionuclide therapy (PRRT).
Besides the kidneys, the bone marrow is a potentially dose-
limiting organ. The radiation dose to the bone marrow is
usually calculated according to the MIRD scheme, where
the accumulated activity in the bone marrow is calculated
fromtheaccumulatedradioactivityoftheradiopharmaceutical
in the blood. This may underestimate the absorbed dose since
stem cells express somatostatin receptors. We verified the
blood-based method by comparing the activity in the blood
with the radioactivity in bone marrow aspirates. Also, we
evaluated the absorbed cross-dose from the source organs
(liver, spleen, kidneys and blood), tumours and the so-called
“remainder of the body” to the bone marrow.
Methods Bone marrow aspirates were drawn in 15 patients
after treatment with [
177Lu-DOTA
0,Tyr
3]octreotate. Radioac-
tivity in the bone marrow was compared with radioactivity in
the blood drawn simultaneously. The nucleated cell fraction
was isolated from the bone marrow aspirate and radioactivity
was measured. The absorbed dose to the bone marrow was
calculated. The results were correlated to the change in
platelet counts 6 weeks after treatment.
Results A strong linear correlation and high agreement
between the measured radioactivities in the bone marrow
aspirates and in the blood was found (r=0.914, p<0.001).
No correlation between the calculated absorbed dose in the
bone marrow and the change in platelets was found. There
was a considerable contribution from other organs and the
remainder of the body to the bone marrow absorbed dose.
Conclusion (1) After PRRT with [
177Lu-DOTA
0,Tyr
3]
octreotate, the radioactivity concentration in the bone
marrow is identical to that in the blood; (2) There is no
significant binding of the radiopharmaceutical to bone
marrow precursor stem cells; (3) The contribution of the
cross dose from source organs and tumours to the bone
marrow dose is significant; and (4) There is considerable
variation in bone marrow absorbed dose between patients.
These findings imply that for individual dose optimization,
individual calculation of the bone marrow absorbed dose is
necessary.
Keywords Dosimetry.Bonemarrow.[
177Lu-DOTA
0,Tyr
3]
octreotate.Therapy.Somatostatinreceptor
Introduction
Peptide receptor radionuclide therapy (PRRT) with radio-
labelled somatostatin analogues, such as [
90Y-DOTA
0,Tyr
3]
octreotide (
90Y-DOTATOC) or [
177Lu-DOTA
0,Tyr
3]octreotate,
has been shown to be an effective treatment in patients with
metastatic neuroendocrine tumours [1–6]. The dose-limiting
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bone marrow [7–9]. In order to avoid toxicity due to absorbed
radiation dose, dosimetry can be performed. While kidney
dosimetry has been investigated extensively [10–12], less
attention has been paid to bone marrow dosimetry.
In order to achieve a maximum antitumour effect,
patients should be treated with the highest justifiable dose
of the radiopharmaceutical that does not cause serious
toxicity. Often the kidneys are the dose-limiting organ.
However, recently it has been shown that the bone marrow
has to be regarded as the dose-limiting organ in approxi-
mately 70% of patients treated with [
177Lu-DOTA
0,Tyr
3]
octreotate [13]. Many studies with radiolabelled somato-
statin analogues have shown that the myelotoxicity is
generally mild and transient [1–3, 6]. However, in a phase
1 study with [
111In-DTPA
0]octreotide 3 out of 50 patients
developed a myelodysplastic syndrome (MDS) which was
probably related to the therapy [14]. Calculations from
these data resulted in an estimated radiation absorbed dose
for the bone marrow of approximately 3 Gy. In another
study with [
177Lu-DOTA
0,Tyr
3]octreotate, MDS was ob-
served in a patient who had had chemotherapy with
alkylating agents 2 years before study entry [15]. In the
latest update of our own records of 504 patients treated with
[
177Lu-DOTA
0,Tyr
3]octreotate, four patients (including the
patient mentioned above) developed MDS [16].
To avoid hypoplasia, a maximum absorbed dose of 2 Gy
to the bone marrow is generally accepted [2, 17]. With a
dose of 2 Gy, the probability for developing leukaemia is
approximately 2% [18]. In radioiodine therapy of metastatic
thyroid cancer a threshold of 2 Gy to the blood as surrogate
for bone marrow has been maintained since the pioneering
work of Benua et al. in 1962 [19]. More recent work has set
this limit to as high as 3 Gy by using more patient-specific
dosimetry techniques [20]. Nevertheless, even if this limit is
not exceeded the risk of the patient developing MDS cannot
be excluded completely, but an accurate estimation of the
absorbed dose to the bone marrow will help find an
adequate dosage.
The absorbed dose to the bone marrow during radio-
nuclide therapies may be estimated with the aid of the
MIRD scheme [21–23]. Contributions to the red marrow
dose (Drm) arise from the accumulated activity in the
marrow tissue itself ~ ArmÞ
 
(self-dose), in source organs
(including tumours and blood) ~ Ah a n di nt h er e m a i n d e ro f
the body ~ Arb:
Drm ¼ ~ ArmSrm rm þ
X ~ AhSrm h þ ~ ArbSrm rb ð1Þ
with Srm←rm the self-dose S-factor, Srm←h the cross-dose
S-factor of the source organs and Srm←rb the cross-dose S-
factor of the remainder of the body. The accumulated
activity of the radiopharmaceutical in the bone marrow is
calculated from the accumulated activity in the blood
(Eq. 2)
~ Arm ¼ ~ A
  
bl   RMBLR  
1:3=57 female ðÞ
1:1=74 male ðÞ
  
  Mpat
ð2Þ
where ½~ A bl is the accumulated activity concentration in the
blood, 1.3/57 and 1.1/74 are the ratios between the red
marrow mass and the total body mass for the adult reference
woman and the adult reference man, respectively, and Mpat is
the mass of the patient in kilograms. Taking into consider-
ation the red marrow to blood concentration ratio (RMBLR),
a correction factor can be added depending on the vector
used for treatment. This method has been validated by bone
marrow aspiration for antibodies but not for radiopeptides
[24, 25].
For radiolabelled somatostatin analogues, the calculation
usually deals with the assumption of absence of specific
uptake of the radiolabel into the bone marrow. Since certain
haematological cells (lymphocytes, monocytes) and hae-
matopoietic progenitor cells express somatostatin receptors,
mainly subtype 2 [26–28], this assumption may result in an
underestimation of the absorbed radiation dose to the bone
marrow. It is not known whether in patients a significantly
higher radioactivity in the bone marrow, compared to the
blood, may be present.
Relevant results for bone marrow dosimetry were
obtained using
86Y as a surrogate for
90Y to calculate the
accumulated dose in the red marrow by PET before
treatment with
90Y-DOTATOC. A region of interest (ROI)
was drawn around a segment of the thoracic spine and
rescaled for the whole red marrow mass using the standard
fraction of active red marrow present in the thoracic spine
[29]. Recently a comparable calculation showing relevant
results as well was presented for iodinated antibodies.
Instead of a PET scan patients underwent a SPECT/CT scan
during therapy [30]. Acquiring a CT scan and using an
integrated SPECT/CT camera allows the ROIs to be placed
anatomically more accurately than using SPECT alone.
This is especially important in radiopharmaceuticals, e.g.
most radiopeptides, which do not show sufficiently high
bone marrow uptake to be indisputably identified on the
scans. In addition the CT scan provides an attenuation map
that can be used to apply an attenuation correction. With
three SPECT scans at different time-points after therapy, we
investigated the feasibility of this calculation in a therapeutic
setting in this study.
In order to verify whether the assumption of no specific
uptake in the bone marrow can be applied with radio-
labelled somatostatin analogues, we compared the radioac-
tivity in bone marrow aspirates with the radioactivity in
blood samples drawn simultaneously. In addition we
Eur J Nucl Med Mol Imaging (2009) 36:1138–1146 1139determined the difference between the radioactivity in the
nucleated cell fraction of the bone marrow, including the
stem cells, and that in the blood to determine whether there
was any difference that could be attributed to the specific
binding of the radiopeptide to somatostatin receptor-
positive cells in the bone marrow. Finally, the absorbed
doses to the bone marrow calculated according to the
MIRD scheme and from the SPECT scans were correlated
with the change in the platelet counts 6 weeks after the
treatment.
Materials and methods
Patients
Included in the study were 15 patients with somatostatin
receptor-positive neuroendocrine tumours. All patients were
admitted to our clinic for PRRT with [
177Lu-DOTA
0,Tyr
3]
octreotate and fulfilled the inclusion criteria as previously
described [6]. None of the patients had known bone
metastases. All patients gave written informed consent to
participate in the study, which was approved by the medical
ethics committee of the hospital.
Comparison of the radioactivity in the bone marrow
and nucleated cell fraction with the radioactivity
in the blood
In addition to the examinations, the treatment, and the scans
that are performed routinely during and after the first
treatment cycle with [
177Lu-DOTA
0,Tyr
3]octreotate,
patients underwent bone marrow aspiration from the iliac
crest 4 days (seven patients), 7 days (seven patients) or
8 days (one patient) after the treatment. A rough differential
count of cells was performed on the bone marrow samples
to prove the presence of a sufficient number of bone
marrow cells and the samples were analysed for haemato-
logical abnormalities. The volume of aspirate was recorded
and the radioactivity was measured in a gamma counter
(Perkin Elmer, Groningen, The Netherlands). One patient
(aspiration 4 days after treatment) was excluded because no
bone marrow could be aspirated. In all patients, a blood
sample was drawn simultaneously to determine the radio-
activity in the blood.
Some of the bone marrow samples and blood samples
were purified for the mononuclear cells (including the stem
cells in the bone marrow samples). The samples (blood 8–
48 mg, 26±12.2 mg, mean±SD; bone marrow 2–49 mg,
22±16.6 mg) were diluted with 5 ml Dispase (Roche
Diagnostics, Almere, The Netherlands) and mixed for
20 min to suspend the cells. Then the samples were diluted
with 50 ml phosphate-buffered saline (PBS) (pH 7.4) and
centrifuged three times for 10 min at 2,500 rpm (about
60 g) each time with washing with 50 ml PBS after every
step. The mononuclear cells, including the stem cells in the
samples from the bone marrow, were isolated by Ficoll-
Paque gradient sedimentation (density 1.077 g/ml; GE
Healthcare Europe, Diegem, The Netherlands). The weight
of the cell pellets was then determined and the radioactivity
was measured in a gamma counter.
Bone marrow dosimetry
For all patients the absorbed radiation dose to the bone
marrow was calculated according to the MIRD scheme
(Eq. 1). The radioactivity concentration in the red marrow
was assumed to be equal to the radioactivity concentration
measured in the blood (RMBLR = 1) [24, 31]. This was
based on at least five blood samples per patient drawn
between 0 and 168 h after injection. Assuming no specific
uptake in the red marrow, a uniform distribution of the
radioactivity, and that the red marrow clearance was the
same as in blood, the self-dose to the red marrow was
calculated. The distribution in the remainder of the body
besides source organs and tumour uptake was assumed to
be homogeneous. In addition, cross-radiation from the liver,
spleen, kidneys, tumour as well as blood was taken into
account. At three different time-points between 24 and
168 h after the administration of [
177Lu-DOTA
0,Tyr
3]
octreotate, scans of tumour deposits, liver, kidney and
spleen were acquired using a dual head camera (Picker
Prism 2000 XP, Philips, Eindhoven, The Netherlands)
using the 208-keV peak. The accumulated activity of the
radiopharmaceutical in tumour and organs (liver, kidneys
and spleen) was calculated from these scans. Attenuation
correction was applied using the data from the pretreat-
ment CT scan. It appeared that in our patient group there
was a high degree of overprojection both for tumours
and organs. As the S-factors of the liver, spleen and
kidneys to the bone marrow were almost the same, the
summation term in Eq. 1 w a sr e g a r d e da sas i n g l es o u r c e
organ.
Urine was collected up to 24 h after treatment and the
radioactivity was measured in a gamma counter. From these
data the accumulated activity in the remainder of the body
(i.e. injected activity minus accumulated activity in source
organs and tumours and minus excreted radioactivity) was
calculated, taking into account the fact that the radioactivity
was overestimated since the urine was collected for 24 h
only. In two patients the radioactivity in the remainder of
the body could not be determined. The quotient of e A and
the injected activity IAyields the residence time t ¼ e A
.
IA
(in hours) for the different organs. The thus calculated
residence times were used as input in the OLINDA program
(Vanderbilt University, Nashville, USA).
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In addition, at three different time-points between 24 and
168 h after treatment, SPECT scans of the thorax were
acquired (energy window 208 keV ±10%, matrix 128×128,
120 projections, 20 s/ per projection).
Correlation with haematological response
Six weeks after the treatment, blood was drawn from 13
patients to determine haematological toxicity after the
treatment. For one patient no blood results were available.
All values were correlated with the decrease in platelet
counts expressed as a percentage of the pretreatment value.
The results of the bone marrow (full bone marrow and
nucleated cell fraction) radioactivity were corrected for
physical decay in order to compare the interindividual
values of the samples drawn at different time-points.
Similarly, calculated absorbed dose to the bone marrow
(self-dose and cross-dose) were correlated with the decrease
in platelet counts.
Statistics
Pearson’s correlation coefficient was calculated. A p value
≤0.05 was considered significant.
Results
The treatment with [
177Lu-DOTA
0,Tyr
3]octreotate was well
tolerated by all patients and no serious adverse events
occurred. The injected radioactivity ranged from 7.26 to
7.75 GBq (7.47±0.10 GBq, mean±SD). On the posttreat-
ment scans all patients showed the expected distribution of
the radiopharmaceutical with specific uptake in all known
tumours. No patient had known or visible bone metastases.
The bone marrow aspirations were uneventful. One
patient had a dry tap. The volume of bone marrow aspirated
in the other patients ranged from 1 to 9.2 g (5.3±2.9 g).
Simultaneously a tube of blood of 2.8 to 7.3 g (5.8±1.3 g)
was drawn. Smears were made from the bone marrow
aspirates. A differential count was performed to establish the
numbers of immature (bone marrow) and mature nucleated
cells. The fraction of immature cells ranged from 25% to
80% (51±15%) indicating that the purified aspirates con-
sisted of a considerable amount of bone marrow and that the
contamination with blood was moderate. A typical example
of a purified bone marrow smear is shown in Fig. 1.
The radioactivity in the full bone marrow samples
ranged from 850 to 4,473 Bq/ml (2,216±899 Bq/ml). The
radioactivity in the blood ranged from 1,077 to 6,451 Bq/ml
(2,437±1,324 Bq/ml). Fitting the correlation line through
the origin (0,0) as seems right from a theoretical point of
view, showed a strong, significant, linear correlation
between the radioactivity determined in the blood and in
the bone marrow aspirate (y=1.13x, r=0.90, p<0.001;
Fig. 2). This results in a mean red marrow over blood ratio
of 0.88 (value not significantly different from 1). Both
qualitatively and quantitatively the results showed strong
agreement over a whole range of activities at the three
different time-points.
The self-absorbed doses to the bone marrow calculated
from the accumulated activity in the blood (Eq. 2),
calculated according to the MIRD scheme, and the changes
in platelet counts after 6 weeks are presented in Table 1.
The contribution of the cross-dose to the red marrow dose
was substantial in relation to the contribution of the self-
dose (Table 1).
No or only very faint uptake in the bone marrow could
be seen on the SPECT scans of the thorax. The bone
marrow to background (ROI placed into the lungs) ratios
were between 1 and 1.8. Therefore it was not possible to
place a ROI reliably, and consequently no absorbed dose to
the bone marrow was calculated from SPECT scans. An
example of transaxial SPECT slices in one patient is shown
in Fig. 3.
No correlation was found between the calculated absorbed
doses to the bone marrow and the decrease in platelet counts,
expressed as a percentage of the pretreatment value.
The correlation between the radioactivity in the full bone
marrow aspirate and the decrease in platelet counts was
poor (r=0.35, p=0.24; Fig. 4). However, the correlation
between the calculated absorbed doses and the decrease in
platelet counts was even less significant.
The ratios of the radioactivity in the isolated mononuclear
cell fraction of the bone marrow to the isolated mononuclear
Fig. 1 Typical example of a smear of a bone marrow aspirate. It
shows a mixture of immature nucleated cells originating from the bone
marrow as well as red blood cells and mature nucleated cells
originating from the peripheral blood
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highly variable. We found ratios ranging from 0.29 to 536
(59.3±143.6). In three patients a higher radioactivity was
found in the mononuclear cells isolated from the blood
whereas 11 patients showed a higher radioactivity in the
mononuclear cells isolated from the bone marrow.
In 11 patients the radioactivity in the isolated mononu-
clear cell fraction, microscopically containing a mixture of
immature and mature cells, could be weight-corrected. In the
other three patients, the isolated fraction could not be
weighted reliably because of the small number of isolated
cells. Weight-corrected ratios of the radioactivity in the
isolated cell fraction of the bone marrow to the isolated cell
fraction of the blood ranged from 0.54 to 133.41 (19.4±38.6).
Only one patient showed a higher radioactivity in the isolated
cell fraction per gram of blood. The correlation coefficient
between the radioactivity per gram in the nucleated cell
fraction of the bone marrow aspirate and the decrease in
platelet count after treatment was r=0.51 (p=0.13; Fig. 5).
From our study this was the best relationship that could be
obtained.
Table 1 Doses to the bone marrow after injection of 3,700 MBq [
177Lu-DOTA
0,Tyr
3]octreotate, and decrease in platelet counts 6 weeks after
treatment
Patient Total absorbed dose to
the red marrow (mGy)
a
Absorbed self-
dose (mGy)
b
Cross-dose (mGy)
c Decrease in platelet count
6weeks after treatment (%)
From the remainder
of the body
From
organs
d
1 40 16 (41%) 12 (31%) 11 (29%) 40
2 82 37 (46%) 26 (32%) 19 (23%) 8
3 212 49 (23%) 152 (72%) 11 (5%) 40
4 108 17 (16%) 83 (77%) 8 (8%) 16
5 64 23 (36%) 26 (41%) 15 (23%) 4
6 129 37 (28%) 78 (61%) 14 (11%) –
7 73 28 (39%) 0 (0%) 45 (61%) −9
8 74 39 (53%) 28 (39%) 6 (9%) −9
92 9 –– 47
10 466 26 (5%) 429 (92%) 11 (2%) 8
11 147 56 (38%) 84 (58%) 7 (5%) 27
12 78 23 (30%) 39 (50%) 16 (20%) 32
13 86 29 (34%) 39 (45%) 18 (21%) 28
14 83 24 (29%) 48 (57%) 12 (14%) 21
Median 83 29 (34%) 39 (50%) 12 (14%) 21
Mean 126 31 (32%) 80 (50%) 15 (18%) 19
SD 111 12 (12%) 112 (24%) 10 (16%) 18
aTaking into account the absorbed self-dose, the cross-dose from the remainder of the body and the absorbed dose of organs and tumour.
bFrom the red marrow to the red marrow.
cTo the red marrow.
dLiver, spleen, kidneys and tumour.
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Fig. 2 Correlation between the activities measured in the bone
marrow aspirate and the activities measured in the blood at the same
time-points. The straight line is the linear regression line: r=0.914,
p<0.001. The slope of the regression line is 1.35 indicating that the
absolute values of the measured activities are also comparable
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Accurate bone marrow dosimetry is mandatory for safe
PRRT. All methods available have certain disadvantages:
aspiration of bone marrow is costly and time consuming,
and it is an invasive procedure associated with a high level
of discomfort for the patients. Calculating the dose to the
red marrow from the accumulated activity concentration in
the blood deals with the assumption that no specific binding
of the radiolabelled somatostatin analogue occurs in the
bone marrow. Also, it neglects the contribution of other
radiation sources in the body, such as organs and tumours,
thereby underestimating the true radiation absorbed dose to
the bone marrow. Alternatively, the determination of the
radioactivity in the remainder of the body (needed for the
MIRD scheme) depends on accuracy in urine collection,
which is subject to errors. Apart from these considerations,
it should be realized that at present none of the diverse
models to estimate the dose to the bone marrow has been
actually confirmed with toxicity data, be it the incidence of
thrombocytopenia or the occurrence of MDS. Apart from
the risk of patients developing MDS, the essential issue of
bone marrow dosimetry is to predict, or better to avoid,
severe haematological toxicity caused by PRRT.
The dose to the red marrow, however, is only one of
several factors influencing the haematological toxicity after
PRRT. A high interpatient variability in the haematological
response after PRRT has been found and also previous
therapies can highly influence the results [2, 29]. Using
different radiopharmaceuticals, some investigators have
found a correlation between haematological toxicity and
injected dose of radioactivity [32, 33], whereas others have
not found such a correlation [34]. It is possible that
additional factors such as age and sex of the patients might
influence the haematological toxicity as well, although in a
trial with radiolabelled antibodies there was only a minor
influence of these factors [35]. As early as the year 2000,
Blumenthal et al reported that plasma levels of FLT3-L help
to predict haematological toxicity after radioimmunotherapy
[36]. In 2003 this was confirmed by Siegel et al. for
radioimmunotherapy with iodinated anti-CEA antibodies
[37]. However, no studies taking this into account have
been published for PRRT. Nevertheless, the importance of
introducing biological parameters into treatment planning is
indisputable [38].
We found a high correlation between the radioactivity
concentration in the blood and in the bone marrow aspirate
during PRRTwith [
177Lu-DOTA
0,Tyr
3]octreotate. The most
probable explanation for the high congruence between the
radioactivity measured in the blood and in the bone marrow
aspirate is that the amount of stem cells in a bone marrow
aspirate is low and that most of the aspirate consists of
blood. On the other hand, the high volume of blood in the
bone marrow aspirate reflects the fact that the blood
contributes most of the self-dose to the bone marrow.
Taking into consideration that the path lengths of the
common therapeutic radionuclides are in the millimetre
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Fig. 5 Correlation between the radioactivity per gram measured in the
isolated mononuclear cell fraction of the bone marrow aspirate with
the decrease in platelet count after treatment. Linear regression
coefficient: r=0.51 (p=0.13)
Fig. 3 Typical example of transverse SPECTslices through the thorax
obtained 24 h after treatment with 7.4 GBq [
177Lu-DOTA
0,Tyr
3]
octreotate. Note that there is no clear uptake over the spine area
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Fig. 4 Plot of the radioactivity in the bone marrow aspirate versus the
percentage decrease in platelet count. The activities measured in the
bone marrow were decay-corrected to the theoretical value on day 8.
Linear regression coefficient: r=0.35 (p=0.24)
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the radiation from the blood will reach all bone marrow
structures.
Promising results for predicting the haematological
response were obtained by using an ROI surrounding a
section of the thoracic spine for determining the absorbed
dose to the red marrow. In these studies the absorbed dose
was calculated with the positron emitter
86Yb e f o r e
treatment with
90Y-DOTATOC [29, 39].
86Y can be
regarded as the ideal surrogate for
90Y and offers a high
resolution when using a PET scanner. However, imaging
with
86Y is currently only available in specialized centres
because besides the need for a cyclotron to produce
86Y, the
reconstruction of the PET data requires sophisticated
correction algorithms. There is certain evidence in literature
that imaging with
86Y might overestimate doses, particu-
larly if the bone marrow is close to dense tissue such as the
spine [40, 41]. Besides, dosimetry using
86Y will be a gold
standard only for treatments with
90Y because in PRRT the
radionuclide used influences the receptor affinity and
consequently the biodistribution of the compound [42].
Moreover, the relatively short physical half-life of
86Y
(14.7 h) does not allow the radioactivity to be followed
over several days which is important for planning of the
treatment with
90Y. However, these results have not yet
been confirmed by another group.
To date one group has found interesting results when
calculating the absorbed radiation dose to the bone marrow
from scans for radiolabelled antibodies using an integrated
SPECT/CT camera [30]. The results have also not been
confirmed by other groups, and no results using this method
with radiopeptides have been published so far. Remarkably
no bone marrow dosimetry was feasible on SPECT scans in
our setting because no or only very faintly visible uptake in
the bone marrow was present on the scans (Fig. 3).
Our results indicate the radioactivity in the blood is a
very accurate surrogate for the radioactivity present in the
bone marrow. However, we also showed that the radioac-
tivity in the remainder of the body as well as the
radioactivity in source organs and tumours significantly
contributes to the absorbed radiation dose to the bone
marrow. With that, our tacit hope that the cumbersome
collection of 24-h urine and time-consuming calculations of
cross-radiation from tumours and organs could be circum-
vented, and that bone marrow absorbed doses could be
derived from blood radioactivity levels only, evaporated.
Also, the bone marrow absorbed dose after treatment with
[
177Lu-DOTA
0,Tyr
3]octreotate showed considerable varia-
tion between patients. This is in contrast with the findings
of a previous pilot study in six patients that showed the
biodistribution of the radiopharmaceutical [43]. These
patients, however, all had a very limited tumour load. The
present series of patients more truly represented the practice
of PRRT in our institution, where the tumour load in
patients is highly variable, and so the contribution of the
cross-dose to the bone marrow is variable as well. This
finding implies that for individual dose optimization,
individual calculation of the bone marrow absorbed dose
is necessary. The results shown in Table 1 indicate that the
remainder of the body as well as organs and tumours
significantly contribute to the absorbed dose to the bone
marrow. Since the contribution to this dose from the
remainder of the body, organs and tumours from the
β-emission of
177Lu is virtually negligible, it appears that
the γ-radiation from tumours, organs and the remainder of
the body contributes to the absorbed bone marrow dose.
We determined the degree of correlation between the
absorbed dose to the red marrow and the decrease in
platelet count after 6 weeks. We focused on platelets only
since platelets show the most pronounced reaction after
PRRT. The degree of correlation between the calculated
absorbed doses to the red marrow and the decrease in
platelet count was disappointing. A number of reasons may
have accounted for this. The absorbed doses were com-
pared with only one posttreatment platelet count. This
platelet count, 6 weeks after treatment, may not have
reflected the nadir in each patient. Another explanation could
have been the relatively small number of patients studied.
Moreover, probably the most important reason could have
been that the response of an individual patient to PRRT is
not only related to the radiation absorbed dose in the bone
marrow but also to the pretreatment status of the bone
marrow. Especially previous, potentially haemocytotoxic
treatments can influence the response after the treatment.
No conclusions can be drawn concerning the relation-
ship between the calculated radiation absorbed dose in the
bone marrow and the risk of developing MDS. However,
developing MDS is probably also related to the pretreat-
ment status of the bone marrow and previous treatments.
Bone marrow dosimetry is a difficult topic. Beside all
factors mentioned above that may influence the dosimetry
of an individual patient, many other considerations have to
be faced. The bone marrow is not a solid organ and simply
the determination of the mass is virtually impossible. As for
all internal radiotherapy treatments, the dose rate in PRRT
is low. Most values that deal with the maximum tolerated
dose of healthy organs are derived from external beam
radiation with a much higher dose rate. The influence of
such physical properties is not well understood and may
highly influence the results of internal dosimetry as much
as the biological response.
In conclusion, our results show that: (1) after PRRT with
[
177Lu-DOTA
0,Tyr
3]octreotate, the radioactivity concentra-
tion in the bone marrow is identical to that in the blood; (2)
there is no significant binding of the radiopharmaceutical to
bone marrow precursor stem cells; (3) the contribution of
1144 Eur J Nucl Med Mol Imaging (2009) 36:1138–1146the cross-dose from source organs and tumours to the bone
marrow dose is significant; (4) there is considerable
variation in bone marrow absorbed dose between patients.
These findings imply that for individual dose optimization,
individual calculation of the bone marrow absorbed dose is
necessary.
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